For the latest COVID-19 Travel restrictions and recommendations please click here

SMi are delighted to present their 10th annual imaging event, Maximising the Value of Imaging in Oncology Drug Development. The event will take place in central London on Wednesday 12 and Thursday 13 March, 2014.


Imaging allows us to answer questions that we did not know the answer to before. For example, it can help determine the composition of the tumour, clinical evaluation of patients and evaluation of new treatments. Imaging within the arena of personalised healthcare is an area of increasing significance and will revolutionise the field of oncology.

The event will focus on innovative imaging and effective strategies for success in oncology drug development. Both pre-clinical and clinical use of imaging will be examined.

Attendees will be given practical tips and guidance on cost-effective imaging management, regulatory insights will be provided and alternatives to costly independent reviews will be discussed. The use of imaging in clinical trials (Phases 2 and 3) will be considered and debated in addition to the use of novel biomarkers.

The event represents an excellent platform in 2014 for learning about the use of imaging pre-clinically and also in clinical trials, giving delegates access to the latest information and key case studies from across the industry.

This 2 day event will be a excellent opportunity for professionals working in imaging to talk to renowned speakers. The event will bring a diverse selection of speakers, representing all areas of the field. From US to UK, attendees will gain a broad analysis of ideas, challenges and solutions. The event will be represent an excellent networking opportunity.

New for 2014:

  • New opportunities for cost-effective imaging management
  • Diverse alternatives to expensive independent reviews - hear from globally recognised experts 
  • Discuss case studies, challenges and opportunities in imaging guidelines featuring Novartis and GSK
  • Gain an in-depth insight into the challenges of imaging in Europe
  • Evaluate the power of new imaging strategies 


Chief Executives, Executive Directors, Vice Presidents, Directors, Heads, Managers, Senior Scientists, Group Leaders of

  • Imaging
  • Medical Imaging
  • Cancer Drug Development
  • Oncology
  • Preclinical oncology
  • Clinical Oncology
  • Research and Development
  • Clinical Technology
  • Specialised Therapeutics
  • Clinical Development
  • Oncology Consultancy
  • Legislation and Policy Advice

Previous attendees from our 2013 conference include:

BioClinica; Biospace Lab; Cancer Research UK; EANM Research; Eisai; Eisai Europe Ltd; Foundation for Liver Research; GLAXOSMITHKLINE; GSK; Hoffmann-La Roche; Imperial College; Intrasense; Ipsen Ltd; MEDIAN Technologies; Medipan Diagnostica; Merck; MRC; Newcastle University; NTEC; Roche Diagnostics; Roche Products; Royal Marsden N H S Trust (The); Sussex University; The Beatson Institute For Cancer Research; UCL Cancer Institute; University College; University of Cambridge and Cancer Research UK; Virtual Scopics L L C; Vision Healthcare Consultancy Ltd; VU University Medical Centre;

Conference programme

8:30 Registration and coffee

9:00 Chairman's Opening Remarks

Peter Eggleton

Peter Eggleton, Medical Director, Merck

9:10 Endpoints and guidelines - thinking outside the box!

Malcolm Barratt-Johnson

Malcolm Barratt-Johnson, Managing Director and Senior Consultant, PharmaMedic Consultancy Ltd

  • Regulation - a help or a hindrance in medical research?
  • The importance of imaging in assessing the efficacy aand safety of medicines
  • Can we do better?
  • 9:50 Raman based analysis of biomarkers, cells, tissue and in vivo targets

    Duncan Graham

    Duncan Graham, Director of the Centre for Molecular Nanometrology, University Of Strathclyde

  • Raman spectroscopy and surface enhanced Raman scattering advantages and disadvantages
  • Applications of SERS in molecular analysis of protein targets for cancer
  • Mapping of biomarkers in cells, tissue and in vivo
  • Working at depth in tissue using optical imaging with nanoparticles
  • 10:30 Accelerating preclinical drug development using in vivo and ex vivo imaging: optimising discovery to delivery

    Werner Scheuer

    Werner Scheuer, Group Leader, Preclinical Optical Imaging, Pharmacology TR-PD, Pharmaceutical Research, Roche Diagnostics

  • Application of different imaging modalities to monitor the efficacy of compounds on primary tumor growth, metastasis and angiogenesis
  • Simultaneous measurement of Pk and Pd
  • Optimising application schedules regarding combination therapies
  • Verification of in vivo imaging data by 3-dimensional multispectral fluorescence histology
  • 11:10 Morning Coffee

    11:30 Molecular imaging in early phase clinical drug development

    Azeem Saleem

    Azeem Saleem, Head of Oncology Applications, Imanova

  • Utility of imaging in early phase clinical trials
  • Study endpoints and study design incorporating molecular imaging in early phase clinical trials
  • Enabling pre-clinical translational issues in the design of clinical trials
  • Ethical, regulatory and operational hurdles in imaging in early stage clinical phase clinical trials
  • 12:10 Networking Lunch

    13:10 Tumour Growth Rate (TGR) as an early indicator of anti-tumour drug activity in Phase I and Phase III clinical trials

    Gerard Nitenberg

    Gerard Nitenberg, Chief Medical Officer, Banook Group

  • The granularity of RECIST 1.1 criteria is insufficient for the early idenitification of patients in whom the treatment may have a beneficial effect
  • Tumour Growth Rate (TGR) allows for the early and precise assessment of the tumour response, by taking into account the pre-treatment tumour kinetics
  • TGR is independently associated with outcome both in early clinical trials and in the Phase III setting
  • The variation of TGR reveals drug-specific profiles, suggesting its potential use for the early assessment of drug activity
  • 13:50 Challenges in developing new imaging agents

    Sabin Carme

    Sabin Carme, Licensing and Business Development, Aviesan

  • Why is it tough to innovate and put on the market new imaging agents? The point of view of a dedicated technology transfer unit in France - Aviesan strategic valorisation in imaging agents
  • Aviesan is the French National Medical Research Institute. Within Aviesan, the valorisation unit is setting up a strategy that includes mapping the molecular imaging agents portfolio from academia as well as building a network of industry partners from the pharmaceutical and diagnostic industry
  • Aviesan valorisation demonstrate the willingness of the imaging community in France to address the challenge in developing new biomarkers imaging methods
  • New paradigms: open innovation, public private partnerships, technology transfer continuum
  • 14:30 Optical molecular imaging of cancer

    Kev Dhaliwal

    Kev Dhaliwal, Senior Clinical Lecturer, Edinburgh University

  • Using imaging approaches to diagnose and stratify cancer
  • Optical molecular imaging: confocal microendoscopy and chemical smartprobes
  • Using drug stratification to deliver better clinical outcomes
  • 15:10 Afternoon Tea

    15:40 PET Imaging in the era of targeted therapies: towards precision medicine

    Gabriela Kramer-Marek

    Gabriela Kramer-Marek, Team Leader, Preclinical Molecular Imaging , Cancer Research UK Centre for Cancer Therapeutics The Institute of Cancer Research

  • Imaging as a cancer biomarker
  • PET targets and probes (eg. affibody molecules)
  • PET goals - i) guide cancer treatment selection
  • PET goals - ii) evaluate treatment response
  • 16:20 Imaging clinically relevant models of human leukaemia and cancers

    Francois Lassailly

    Francois Lassailly, Head, In-Vivo Imaging, Cancer Research UK

  • Donor and patient derived xenografts, GEMMs
  • Optical (bioluminescence and fluorescence), micro-CT, ultrasound and intravital microscopy
  • Monitoring disease progression and response to treatment
  • Evaluation and validation of probes
  • Remaining challenges and future developments
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Registration and coffee

    9:00 Chairman's Opening Remarks

    Malcolm Barratt-Johnson

    Malcolm Barratt-Johnson, Managing Director and Senior Consultant, PharmaMedic Consultancy Ltd

    9:10 Imaging and microdosing for pharmacokinetics of (bio)pharmaceuticals

    Marijn Vlaming

    Marijn Vlaming, Research Scientist, TNO

  • First-in-human microtracer studies for drug development
  • Future of microtracer studies for (bio)pharmaceutical development
  • Imaging biodistribution of (bio)pharmaceuticals in disease models
  • Imaging drug transporters at the blood-brain barrier
  • 9:50 The challenges of a multicentre imaging study

    Nazar Amso

    Nazar Amso, Deputy Director, Innovation and Engagement , Cardiff University

  • Gaining an insight into the Ovarian Cancer Screening study
  • Setting scanning standards and continuing professional development
  • Quality assurance of sonography practice
  • Conclusions discussed
  • 10:30 Morning Coffee

    11:00 The implementation of audit methodologies in oncology clinical trials

    Annette Schmid

    Annette Schmid, Head of Oncology Strategy, Perceptive Informatics Inc

  • What is the goal of such audit methods?
  • What data and updates are available since the initial ODAC meeting
  • What are the currently known risks and recommendations
  • 11:40 Impact of electronic transfer of scans on imaging trials

    Veronique Bragulat

    Veronique Bragulat, Clinical Imaging Manager, GSK

  • Introduction to imaging at GSK
  • Traditional courier method versus electronic transfer of scans
  • Trial and workflow optimisation
  • Trends/metrics and industry uptake
  • 12:20 Networking Lunch

    13:50 Blinded Independent Central Review in Oncology Trials

    Lori Dodd

    Lori Dodd, Mathematical Statistician, National Institute Of Allergy And Infectious Diseases / N I H

  • Progression-free survival as an endpoint in registration trials
  • What does blinded independent central review contribute to registration trials with a PFS endpoint?
  • Potential solutions to problems introduced by blinded independent review
  • Benefits and limitations of an audit using blinded independent central review
  • 14:30 Afternoon Tea

    15:00 Pearls and pitfalls of implementing imaging in multicentre clinical trials

    Yan Liu

    Yan Liu, Head of Translational Research, Radiotherapy and Imaging, EORTC

  • Value of imaging in personalised medicine
  • Challenges of imaging biomarker development
  • Imaging biomarker validation
  • Public and private collaboration in imaging biomarker development (eg. QuIC -ConCePT - IMI Project)
  • 15:40 Imaging in multicentre clinical trials: A European Perspective

    Vicky Goh

    Vicky Goh, President, European Society of Oncologic Imaging

  • Current challenges for oncologic imaging in Europe
  • Meeting the needs of pharmaceutical companies and oncologists
  • New opportunities for an integrative approach across Europe via a European Network of Excellence
  • 16:20 Chairman's Closing Remarks and Close of Day Two





    Holiday Inn Regents Park
    11th March 2014
    London, United Kingdom

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out